

Medi-Cal Contract Drug Advisory Committee (MCDAC) Disclosures of Conflicts

The following principles guide the **Medi-Cal MCDAC** management of conflicts of interest:

- Committee members shall disclose and report on an annual basis any relationship with a pharmaceutical manufacturer or other vendor that they know or have reason to know will have a financial effect, distinguishable from its effect on the public generally, on his/her personal financial interests or in the financial interests of an immediate family member or business partner.
- For purposes of this disclosure statement, the following definitions apply:
 - Financial effects or interests refers to reasonably material financial effects or interests that include but are not limited to: receiving research funds, actively investing as an investor in individual pharmacy or medical device company stock, maintaining consulting relationships, and receiving gifts and/or honoraria with a cumulative annual value greater than a \$1000 from a drug company, and any other vendor or potential vendor.
 - Immediate family member or business partner refers to a spouse or legally recognized domestic partner, a parent (natural or step), a child (natural or step), and any other individual with whom the signee has a legally binding financial relationship.
- A Committee member with a reasonably foreseeable material financial interest with regard to a product being discussed by the Committee shall recuse him/herself or disclose verbally his/her financial interest to the Committee.

I, the undersigned (or an immediate family member or business partner), have financial interest with the following manufacturers or vendors:

Financial Interest

Manufacturer(s)/Vendor(s)/Potential Vendors

Grants/Research Support

Consultant

Active Shareholder/Investor

Speakers Bureau/Honorarium

Other Financial or Material Support

None

Comments:

Signature: _____ Date: _____

Print/Type Name: